Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells 8,562 Shares

Posted by George Bondi on Aug 25th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) insider Eric Duane Foster sold 8,562 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $33,049.32. Following the completion of the transaction, the insider directly owned 409,410 shares in the company, valued at approximately $1,580,322.60. This represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ardelyx Stock Performance

Shares of Ardelyx stock traded up $0.04 during midday trading on Tuesday, hitting $3.78. The company had a trading volume of 3,418,138 shares, compared to its average volume of 5,069,888. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.34 and a quick ratio of 3.15. Ardelyx, Inc. has a 1-year low of $3.72 and a 1-year high of $8.40. The business’s 50 day simple moving average is $4.97 and its two-hundred day simple moving average is $5.75. The stock has a market cap of $941.94 million, a PE ratio of -17.18 and a beta of 0.70.

Ardelyx (NASDAQ:ARDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The company had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. During the same quarter last year, the company earned ($0.08) earnings per share. The business’s revenue was up 34.3% on a year-over-year basis. As a group, equities analysts predict that Ardelyx, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARDX has been the topic of several research analyst reports. Zacks Research cut Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. BTIG Research decreased their price objective on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Weiss Ratings downgraded shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. Citigroup reduced their target price on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Ardelyx in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.90.

Check Out Our Latest Analysis on ARDX

Hedge Funds Weigh In On Ardelyx

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Ardelyx in the second quarter worth about $119,874,000. Vanguard Group Inc. raised its holdings in Ardelyx by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company’s stock worth $110,650,000 after purchasing an additional 610,162 shares during the last quarter. Janus Henderson Group PLC lifted its position in Ardelyx by 5.0% during the 4th quarter. Janus Henderson Group PLC now owns 14,514,692 shares of the biopharmaceutical company’s stock valued at $84,583,000 after purchasing an additional 690,599 shares during the period. State Street Corp boosted its stake in shares of Ardelyx by 22.6% in the 4th quarter. State Street Corp now owns 11,912,339 shares of the biopharmaceutical company’s stock valued at $69,449,000 after purchasing an additional 2,193,649 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Ardelyx by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 5,827,618 shares of the biopharmaceutical company’s stock valued at $33,981,000 after purchasing an additional 70,832 shares during the last quarter. Institutional investors own 58.92% of the company’s stock.

About Ardelyx

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.